Analysis of CYP17 gene polymorphism on increasing androstenedione levels in polycystic ovary syndrome women with obesity in Surabaya

Introduction: CYP17 gene polymorphism causes susceptibility, can interfere with the enzyme biosynthesis mechanism in steroidogenesis, and becomes a possible genetic factor for hyper-androgen in PCOS. The study aimed to analyze the relationship between CYP17 gene polymorphism and increased androstenedione levels in PCOS women with obesity. Methods: This study is an observational case-control analytic. The sample is 23 obese PCOS women and 23 obese non-PCOS women, using a purposive sampling technique. CYP17 gene polymorphism examination with PCR and RFLP. Examination of androstenedione hormone by ELISA. The examination results were tested using a logistic regression statistical test with α = 0.05, the hypothesis being accepted if p-value <0.005. Results: The study subjects were 20-30 years old, 50-60 kg body weight, with BMI more than 25%. The distribution of CYP17 gene genotypes in the case group was TC, 47.8%, while in the control group, it was TT, 100%, Chi-Square test on CYP17 gene polymorphism in PCOS and control groups showed significant differences (P 0.000). Wilcoxon-Mann Whitney test of androstenedione levels in cases compared to controls P = 0.000, eta CYP17 correlation test with androstenedione levels P = 0.061. Conclusion: There is a difference in CYP 17 gene polymorphism in obese PCOS women compared to obese non-PCOS women. Androstenedione levels are higher in PCOS women than in obese non-PCOS women and there is no association of CYP17 with Androstenedione levels in PCOS women with obesity.